Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

Clinical Pharmacokinetics

Volumn 42, Issue 3, 2003, Pages 283-292

  Brenner, Stefanie S ^a   Herrlinger, Charlotte ^a   Dilger, Karin ^a   Mürdter, Thomas E ^a   Hofmann, Ute ^a   Marx, Claudia ^a   Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; DICLOFENAC; DNA;

ADULT; AGE; AGED; ALLELISM; ANALGESIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DNA SEQUENCE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ELDERLY CARE; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADULT; AGED; AGING; ALLELES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0037226087     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342030-00003     Document Type: Article

References (48)

1. Thomson AH, Tucker GT. Gerontokinetics: a reappraisal. Br J Clin Pharmacol 1992; 33: 1-2
2. Avorn J. Including elderly people in clinical trials. BMJ 1997; 315: 1033-4
3. Greengross S, Murphy E, Quam L, et al. Aging: a subject that must be at the top of world agendas. BMJ 1997; 315: 1029-30
4. Winker MA. Aging: a global issue [letter]. JAMA 1997; 278: 1377
5. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995; 7: 10-8
6. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 1997; 33: 302-12
7. Hughes SG. Prescribing for the elderly patient: why do we need to exercise caution? Br J Clin Pharmacol 1998; 46: 531-3
8. Turnheim K. Drug dosage in the elderly: is it rational? Drugs Aging 1998; 13: 357-79
9. Le Couteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359-73
10. Hämmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 35: 49-64
11. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15: 897-918
12. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33: 184-213
13. Woodhouse KW, Wynne H. The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet 1987; 12: 111-22
14. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 2000; 59: 1207-16
15. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42
16. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38: 225-42
17. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59: 957-80
18. Paulson SK, Hribar JD, Liu NW, et al. Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metab Dispos 2000; 28: 308-14
19. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1993; 52: 29-34
20. Tang C, Shou M, Mei Q, et al. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 2000; 293: 453-9
21. Shimamoto J, Ieiri I, Urae A, et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 2000; 56: 65-8
22. Morin S, Loriot MA, Poirier JM, et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 2001; 56: 793-7
23. Tang C, Shou M, Rushmore TH, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11: 223-35
24. Schönberger F, Heinkele G, Mürdter TE, et al. Simple method for the determination of celecoxib in human serum by HPLC with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 768: 255-60
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-binding. Anal Biochem 1976; 72: 248-54
26. Wang S, Huang J, Lai MD, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction. Pharmacogenetics 1995; 5: 37-42
27. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9
28. Tanswell P, Heinzel G, Weisenberger H, et al. Pharmacokinetic-pharmacodynamic and metabolite modeling with TopFit. Int J Clin Pharmacol Ther 1995; 33: 550-4
29. Haslock I. Clinical economics review: gastrointestinal complications of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1998; 12: 127-33
30. Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol 2001; 61: 631-7
31. Eras J, Perazella MA. NSAIDs and the kidney revisited: are selective cyclooxygenase-2 inhihitors safe? Am J Med Sci 2001; 321: 181-90
32. Pacifici GM, Viani A. Methods of determining plasma and tissue hinding of drugs: pharmacokinetic consequences. Clin Pharmacokinet 1992; 23: 449-68
33. Paulson SK, Kaprak TA, Gresk CJ, et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos 1999; 20: 293-9
34. Schall R, Hundt HKL, Luus HG. Pharmacokinetic characteristics of absorption and clearance in drug/drug interaction studies. Int J Clin Pharmacol Ther 1994; 32: 633-7
35. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187-216
36. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998; 23: 247-55
37. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin: nature or nurture? Clin Pharmacol Ther 2001; 70: 159-64
38. Stubbins MJ, Hurries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429-39
39. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2 C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-10
40. García-Martín E, Martínez C, Ladero JM, et al. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001; 57: 47-9
41. Yasar Ü, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-31
42. Aynacioglu AS, Brockmöller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-15
43. Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50
44. Yoon YR, Shon JH, Kim MK, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-80
45. Martin JH, Begg EJ, Kennedy MA. et al. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol 2001; 51: 627-30
46. Yasar Ü, Eliasson E, Forslund C, et al. Metabolism of losartan and diclofenac by polymorphic CYP2C9 [abstract]. Drug Metab Rev 2001; 33 Suppl. 1: 225
47. Yasar Ü, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57: 729-35
48. Chen M-L, Lesko L, Williams RL. Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet 2001; 40: 565-72